190 related articles for article (PubMed ID: 31600525)
41. Modified plasma and abomasal disposition of albendazole in nematode-infected sheep.
Alvarez LI; Sánchez SF; Lanusse CE
Vet Parasitol; 1997 May; 69(3-4):241-53. PubMed ID: 9195734
[TBL] [Abstract][Full Text] [Related]
42. Effect of treatment with free and liposomized albendazole on selected immunological parameters and cyst growth in mice infected with Echinococcus multilocularis.
Dvoroznáková E; Hrcková G; Borosková Z; Velebný S; Dubinský P
Parasitol Int; 2004 Dec; 53(4):315-25. PubMed ID: 15464441
[TBL] [Abstract][Full Text] [Related]
43. Dose dependent pharmacokinetics of albendazole in human.
Mirfazaelian A; Rouini MR; Dadashzadeh S
Biopharm Drug Dispos; 2002 Dec; 23(9):379-83. PubMed ID: 12469331
[TBL] [Abstract][Full Text] [Related]
44. Depletion study and estimation of the withdrawal period for albendazole in tambaqui (
Pereira Cordeiro R; Aparecida de Campos Braga P; Souza Rocha MJ; Campos Chagas E; Reyes Reyes FG
Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2021 Nov; 38(11):1883-1896. PubMed ID: 34477497
[TBL] [Abstract][Full Text] [Related]
45. Time dependent pharmacokinetics of albendazole in human.
Mirfazaelian A; Rouini MR; Dadashzadeh S
Biopharm Drug Dispos; 2003 Jul; 24(5):199-204. PubMed ID: 12784319
[TBL] [Abstract][Full Text] [Related]
46. The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis.
Romo ML; Wyka K; Carpio A; Leslie D; Andrews H; Bagiella E; Hauser WA; Kelvin EA;
Trans R Soc Trop Med Hyg; 2015 Nov; 109(11):738-46. PubMed ID: 26433183
[TBL] [Abstract][Full Text] [Related]
47. [Preparation of albendazole polybutycyanocrylate nanoparticles and study on its pharmaceutical properties and tissue distribution].
Zhang XN; Zhang Q; Wen H; Wang GQ; Sun DJ
Yao Xue Xue Bao; 2003 Jun; 38(6):462-6. PubMed ID: 14513810
[TBL] [Abstract][Full Text] [Related]
48. Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence.
Mingjie W; Shuhua X; Junjie C; Bin L; Cheng F; Weixia S; Hotez P
Acta Trop; 2002 Aug; 83(2):177-81. PubMed ID: 12088859
[TBL] [Abstract][Full Text] [Related]
49. Enhanced dissolution and systemic availability of albendazole formulated as solid dispersions.
Castro SG; Sanchez Bruni SF; Urbizu LP; Confalonieri A; Ceballos L; Lanusse CE; Allemandi DA; Palma SD
Pharm Dev Technol; 2013; 18(2):434-42. PubMed ID: 22670782
[TBL] [Abstract][Full Text] [Related]
50. Disposition kinetics of albendazole and metabolites in laying hens.
Bistoletti M; Alvarez L; Lanusse C; Moreno L
J Vet Pharmacol Ther; 2013 Apr; 36(2):161-8. PubMed ID: 22533477
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of albendazole prodrugs in experimental trichinellosis.
Yépez-Mulia L; Morales-Hurtado R; Viveros-Guzmán N; Cedillo-Rivera R; Hernández-Luis F; Castillo R; Hernández-Campos A; Muñoz O
Arch Med Res; 1999; 30(5):368-74. PubMed ID: 10596455
[TBL] [Abstract][Full Text] [Related]
52. Influence of surfactants on oral bioavailability of albendazole based on the formation of the sulphoxide metabolites in rats.
Redondo PA; Alvarez AI; García JL; Villaverde C; Prieto JG
Biopharm Drug Dispos; 1998 Jan; 19(1):65-70. PubMed ID: 9510986
[TBL] [Abstract][Full Text] [Related]
53. Enhanced plasma and target tissue availabilities of albendazole and albendazole sulphoxide in fasted calves: evaluation of different fasting intervals.
Sánchez S; Alvarez L; Sallovitz J; Lanusse C
J Vet Pharmacol Ther; 2000 Aug; 23(4):193-201. PubMed ID: 11126322
[TBL] [Abstract][Full Text] [Related]
54. Albendazole nanocrystals in experimental alveolar echinococcosis: Enhanced chemoprophylactic and clinical efficacy in infected mice.
Pensel P; Paredes A; Albani CM; Allemandi D; Sanchez Bruni S; Palma SD; Elissondo MC
Vet Parasitol; 2018 Feb; 251():78-84. PubMed ID: 29426481
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis.
Lanchote VL; Garcia FS; Dreossi SA; Takayanagui OM
Ther Drug Monit; 2002 Jun; 24(3):338-45. PubMed ID: 12021623
[TBL] [Abstract][Full Text] [Related]
56. Comparative drug systemic exposure and clinical efficacy against resistant nematodes in lambs treated with different albendazole formulations.
Suárez G; Alvarez L; Castells D; Correa O; Fagiolino P; Lanusse C
J Vet Pharmacol Ther; 2011 Dec; 34(6):557-64. PubMed ID: 21371047
[TBL] [Abstract][Full Text] [Related]
57. Quantitative determination of albendazole and its main metabolites in plasma.
Garcia JJ; Bolás-Fernández F; Torrado JJ
J Chromatogr B Biomed Sci Appl; 1999 Feb; 723(1-2):265-71. PubMed ID: 10080654
[TBL] [Abstract][Full Text] [Related]
58. Comparative plasma disposition kinetics of albendazole, fenbendazole, oxfendazole and their metabolites in adult sheep.
Lanusse CE; Gascon LH; Prichard RK
J Vet Pharmacol Ther; 1995 Jun; 18(3):196-203. PubMed ID: 7674455
[TBL] [Abstract][Full Text] [Related]
59. Partial inhibition of the main energetic pathways and its metabolic consequences after
Picanço GA; de Lima NF; Gomes TC; Fraga CM; Alves DSMM; Castillo R; da Costa TL; Lino-Junior RS; Ambrosio J; Vinaud MC
Parasitology; 2019 Oct; 146(12):1578-1582. PubMed ID: 31303189
[TBL] [Abstract][Full Text] [Related]
60. Sensitive in vitro system to assess morphological and biochemical effects of praziquantel and albendazole on Taenia solium cysts.
Mahanty S; Paredes A; Marzal M; Gonzalez E; Rodriguez S; Dorny P; Guerra-Giraldez C; Garcia HH; Nash T
Antimicrob Agents Chemother; 2011 Jan; 55(1):211-7. PubMed ID: 21041508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
